Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 25, 2012 (14 years ago)

Epinephrine Injection USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulates; may contain glass particles

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Epinephrine Injection USP, 1 mL, USP 1:1000 (1 mg/mL), SQ/IM, Hospira, Inc., Lake Forest, IL --- NDC 0409-7241-01

Affected NDC 0409-7241-01

Compare with the code on your package — it is the most precise check available.

Drug: Epinephrine

Recalling firm
Hospira Inc.
NDC code
0409-7241-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-106-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Epinephrine recalls

See all
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0387-2026

Other recalls by Hospira Inc.

All 2012 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016